Literature DB >> 28878334

Vasculitis syndromes: Tocilizumab - a new frontier for GCA therapy.

Matthew J Koster1, Kenneth J Warrington1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28878334     DOI： 10.1038/nrrheum.2017.150

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.

Authors:  Carol A Langford; David Cuthbertson; Steven R Ytterberg; Nader Khalidi; Paul A Monach; Simon Carette; Philip Seo; Larry W Moreland; Michael Weisman; Curry L Koening; Antoine G Sreih; Robert Spiera; Carol A McAlear; Kenneth J Warrington; Christian Pagnoux; Kathleen McKinnon; Lindsy J Forbess; Gary S Hoffman; Renée Borchin; Jeffrey P Krischer; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2017-03-03       Impact factor: 10.995

2.  Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.

Authors:  Katie Tuckwell; Neil Collinson; Sophie Dimonaco; Micki Klearman; Daniel Blockmans; Elisabeth Brouwer; Maria C Cid; Bhaskar Dasgupta; Juergen Rech; Carlo Salvarani; Sebastian H Unizony; John H Stone
Journal:  Semin Arthritis Rheum       Date:  2016-11-15       Impact factor: 5.532

3.  Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.

Authors:  S Unizony; L Arias-Urdaneta; E Miloslavsky; S Arvikar; A Khosroshahi; B Keroack; J R Stone; J H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-11       Impact factor: 4.794

4.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Peter M Villiger; Sabine Adler; Stefan Kuchen; Felix Wermelinger; Diana Dan; Veronika Fiege; Lukas Bütikofer; Michael Seitz; Stephan Reichenbach
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

5.  Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation).

Authors:  Ana García-Martínez; Pedro Arguis; Sergio Prieto-González; Georgina Espígol-Frigolé; Marco A Alba; Montserrat Butjosa; Itziar Tavera-Bahillo; José Hernández-Rodríguez; Maria C Cid
Journal:  Ann Rheum Dis       Date:  2013-07-19       Impact factor: 19.103

6.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.

Authors:  Alfred D Mahr; Juan A Jover; Robert F Spiera; César Hernández-García; Benjamin Fernández-Gutiérrez; Michael P Lavalley; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2007-08

Review 7.  Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis.

Authors:  Matthew J Koster; Eric L Matteson; Kenneth J Warrington
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

Review 8.  Immune mechanisms in medium and large-vessel vasculitis.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  Nat Rev Rheumatol       Date:  2013-11-05       Impact factor: 20.543

9.  Trial of Tocilizumab in Giant-Cell Arteritis.

Authors:  John H Stone; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Martin Aringer; Daniel Blockmans; Elisabeth Brouwer; Maria C Cid; Bhaskar Dasgupta; Juergen Rech; Carlo Salvarani; Georg Schett; Hendrik Schulze-Koops; Robert Spiera; Sebastian H Unizony; Neil Collinson
Journal:  N Engl J Med       Date:  2017-07-27       Impact factor: 91.245

10.  Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients.

Authors:  Joseph J Maleszewski; Brian R Younge; John T Fritzlen; Gene G Hunder; Jorg J Goronzy; Kenneth J Warrington; Cornelia M Weyand
Journal:  Mod Pathol       Date:  2017-03-03       Impact factor: 7.842
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.